Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Craving Management Program for Substance Use Disorders

7. Juli 2026 aktualisiert von: Hae Kook Lee, The Catholic University of Korea

A Preliminary Study on the Effectiveness of a Psychosocial Treatment Program (Craving Management and Alternative Behavior Enhancement Program) for Substance Use Disorders

This study examines whether a newly developed eight-session psychosocial treatment program, called the Craving Management and Alternative Behavior Enhancement Program, can be delivered in real-world hospital settings to people receiving inpatient care for substance use disorders in Korea, and whether it shows early signs of benefit. The program combines motivational interviewing, acceptance and commitment therapy, behavioral activation, and group activities, and is delivered twice a week over about four weeks (eight 50-minute sessions). About 20 adults will take part at two psychiatric hospitals.

Participants complete brief questionnaires and a short interview about their craving, motivation to change, behavioral activation, positive and negative affect, mindfulness, and drug use history before the program, immediately before and after each session, within one week after the program ends, and again at 1 month and 3 months after completion. After the program, some participants also join a small group discussion (focus group interview) to share their experience of the program.

Because this is a small, single-group preliminary (pilot) study without a comparison group, its primary purpose is to assess feasibility, that is, whether the program and the assessment approach work well enough, and to obtain preliminary effect and variability estimates to inform the design of a future large-scale randomized controlled trial.

Studienübersicht

Detaillierte Beschreibung

Background: Substance use among the Korean population has increased rapidly, with spread into adolescents and people in their twenties. Yet standardized, evidence-based psychosocial treatment programs and a corresponding clinician training and certification system are not well established in Korea. Evidence-based psychosocial interventions such as cognitive behavioral therapy, motivational interviewing, community reinforcement approaches, and 12-step facilitation are widely used as standard care in other countries, but comparable, locally validated programs are scarce in Korea. To address this gap, a Korean psychosocial treatment program (the Craving Management and Alternative Behavior Enhancement Program) was developed, and this preliminary study evaluates its feasibility and preliminary effectiveness.

Objectives:

  1. Primary objective: to evaluate the real-world feasibility of delivering the Craving Management and Alternative Behavior Enhancement Program to inpatients with substance use disorders.
  2. Secondary objective: to examine preliminary changes in craving (VAS-C), motivation to change (URICA-DO), behavioral activation (K-BADS-SF), positive and negative affect (K-PANAS-SF), mindfulness (K-MMAS), and drug use history and treatment service utilization, and to assess whether these measures are suitable for a future comparative trial.
  3. Tertiary objective: to explore participants' subjective experience and the acceptability of the program through a focus group interview, in order to refine the treatment manual and operational protocol for a future randomized controlled trial.

Design and setting: This is a single-arm, pre-post study with follow-up, without a control group. A total of 20 participants (10 per site) will be enrolled at two psychiatric hospitals that provide care to a large proportion of patients with drug use disorders in Korea (Incheon Chamsarang Hospital and Daegu Daedong Hospital). Study planning, rater training, informed consent storage, data management, and statistical analysis are coordinated centrally by the Catholic University of Korea. The two participating sites do not have their own IRB and are reviewed under the Uijeongbu St. Mary's Hospital IRB.

Intervention: The program consists of eight 50-minute group sessions delivered twice weekly over approximately four weeks. It integrates motivational interviewing, acceptance and commitment therapy, behavioral activation, and group therapy. Session themes are: (1) how craving arises; (2) craving regulation strategies I: the pause between impulse and action; (3) craving regulation strategies II: from automatic reactions to chosen responses; (4) anticipating high-risk situations and building a personal coping card; (5) identifying alternative behaviors that fit one's own life; (6) building small but reliable routines; (7) noticing positive moments and cultivating gratitude; and (8) creating a personal recovery practice manual.

Assessment schedule: Baseline assessment occurs within one week before the program. Craving is assessed immediately before and after each session, along with session satisfaction and a therapist treatment-fidelity self-assessment. Post-intervention assessment occurs within one week after the program, followed by a focus group interview. Follow-up assessments are conducted at 1 month and 3 months after program completion.

Statistical analysis: Feasibility will be summarized using recruitment, retention, session attendance, and assessment completion rates. Change in continuous outcomes over time (pre, post, follow-up) will be analyzed using repeated-measures analysis of variance and linear mixed models; where covariate adjustment for repeated measures is needed, generalized estimating equations will be used. Analyses adjust for sociodemographic covariates and indication variables, or use stratified comparison. Missing data judged to be MCAR/MAR will be handled via maximum likelihood estimation within linear mixed models or multiple imputation, with sensitivity analyses. The main analysis is based on the full analysis set, with the per-protocol set as a supportive analysis. Qualitative focus group data will be transcribed and analyzed using thematic analysis (Braun & Clarke, 2006) by at least two independent coders.

Studientyp

Interventionell

Einschreibung (Geschätzt)

20

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Daegu, Südkorea
        • Daegu Daedong Hospital
        • Kontakt:
      • Incheon, Südkorea
        • Incheon Chamsarang Hospital
        • Kontakt:
          • Younghoon Chon, MD, PhD
          • Telefonnummer: +82-32-571-9111
          • E-Mail: 8542231@daum.net

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Adults aged 19 to 65 years who can understand the study purpose and procedures and provide written informed consent
  • Currently hospitalized (inpatient)
  • Able to communicate and complete questionnaires in Korean
  • Physically able to participate in program activities
  • Has completed detoxification treatment
  • Meets indication thresholds: DAST-10 score >= 2, craving reported as present on the VAS-C craving screening (i.e., "yes"), and >= 2 DSM-5 criteria

Exclusion Criteria:

  • Cognitive impairment that precludes communication
  • Physical conditions that preclude program participation (e.g., musculoskeletal disorder, severe cardiopulmonary disease)
  • Acute psychotic symptoms or risk of self-harm or harm to others
  • At risk of disrupting group activities such that focus group participation is not feasible
  • Individuals who are inmates or incarcerated at screening are not enrolled; participants who become incarcerated after enrollment are withdrawn

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Craving Management and Alternative Behavior Enhancement Program
All participants receive the Craving Management and Alternative Behavior Enhancement Program, an eight-session group-based psychosocial treatment delivered twice weekly (50 minutes per session) over approximately four weeks. The program integrates motivational interviewing, acceptance and commitment therapy, behavioral activation, and group therapy, covering craving awareness, craving-regulation strategies, high-risk situation coping, alternative behaviors, routine building, gratitude, and a personalized recovery plan.
Eight 50-minute group sessions delivered twice weekly over approximately four weeks. Session 1: how craving arises. Session 2: craving regulation strategies I (the pause between impulse and action). Session 3: craving regulation strategies II (from automatic reactions to chosen responses). Session 4: anticipating high-risk situations and building a personal coping card. Session 5: identifying alternative behaviors that fit one's own life. Session 6: building small but reliable routines. Session 7: noticing positive moments and cultivating gratitude. Session 8: creating a personal recovery practice manual. Core techniques are motivational interviewing, acceptance and commitment therapy, behavioral activation, and group therapy.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Craving (VAS-C)
Zeitfenster: Immediately before and immediately after each of the 8 sessions (over approximately 4 weeks); baseline (within 1 week before the program); within 1 week post-intervention; 1 month and 3 months after completion
Craving measured by the Visual Analog Scale for Craving (VAS-C), ranging from 0 to 100 mm (0 = no craving, 100 = constant craving); higher scores indicate greater craving (worse outcome). Change from baseline is assessed at post-intervention and follow-up.
Immediately before and immediately after each of the 8 sessions (over approximately 4 weeks); baseline (within 1 week before the program); within 1 week post-intervention; 1 month and 3 months after completion
Feasibility: Program Completion (Retention) Rate
Zeitfenster: From enrollment through the end of the 8-session intervention (approximately 4 weeks)
Proportion of enrolled participants who complete all eight sessions of the Craving Management and Alternative Behavior Enhancement Program. Feasibility is further characterized by recruitment rate, session attendance, and assessment completion rates.
From enrollment through the end of the 8-session intervention (approximately 4 weeks)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Drug Use and Treatment Service Utilization
Zeitfenster: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Self-reported drug use history and treatment service utilization assessed via a structured 1:1 interview. Recall window is the past 30 days at most time points and the past 2 months at the 3-month follow-up.
Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Change in Motivation to Change (URICA-DO)
Zeitfenster: Baseline (within 1 week before program), post-intervention (within 1 week after program), 1 month and 3 months after completion
Motivation to change (readiness) measured by the Korean version of the University of Rhode Island Change Assessment for Drug Offenders (URICA-DO), a 24-item scale rated from 1 (strongly disagree) to 5 (strongly agree) with four subscales (Precontemplation, Contemplation, Action, Maintenance). A Readiness to Change score is computed as the sum of the mean Contemplation, Action, and Maintenance subscale scores minus the mean Precontemplation subscale score (range -2 to 14); higher scores indicate greater readiness to change (better outcome).
Baseline (within 1 week before program), post-intervention (within 1 week after program), 1 month and 3 months after completion
Program Acceptability (Focus Group Interview)
Zeitfenster: Within 1 week after program completion
Acceptability and subjective experience of the program explored through a focus group interview using a semi-structured guide, analyzed by thematic analysis (Braun & Clarke, 2006).
Within 1 week after program completion
Change in Behavioral Activation (K-BADS-SF)
Zeitfenster: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Behavioral activation measured by the Korean version of the Behavioral Activation for Depression Scale-Short Form (K-BADS-SF), a 9-item scale rated from 0 to 6, with avoidance/rumination items reverse-scored; higher total scores indicate greater behavioral activation (better outcome).
Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Change in Mindfulness (K-MMAS)
Zeitfenster: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion
Mindful attention and awareness measured by the Korean version of the Mindful Attention Awareness Scale (K-MMAS), a 15-item scale rated from 1 to 7 (total range 15 to 105); higher scores indicate greater mindful attention and awareness (better outcome).
Baseline, post-intervention (within 1 week), 1 month and 3 months after completion

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Session Usefulness and Therapeutic Alliance
Zeitfenster: Immediately after each of the 8 sessions (over approximately 4 weeks)
Participant-rated helpfulness of each session and therapeutic alliance on a visual analog scale from 0 to 10 (0 = not helpful at all, 10 = very helpful); higher scores indicate greater perceived usefulness and alliance (better outcome).
Immediately after each of the 8 sessions (over approximately 4 weeks)
Treatment Fidelity (Adherence Rate)
Zeitfenster: Immediately after each of the 8 sessions
Therapist self-assessed treatment fidelity comprising common structural-fidelity items, session-specific core-practice items, and overall clinical-process fidelity items (yes/no), summarized as an adherence rate per session and per therapist.
Immediately after each of the 8 sessions

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Hae Kook Lee, MD, PhD, Study Principal Investigator

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. August 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2026

Studienabschluss (Geschätzt)

1. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

7. Juli 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

7. Juli 2026

Zuerst gepostet (Tatsächlich)

13. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

7. Juli 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

This is a small, single-group pilot study involving sensitive data from patients with substance use disorders. Given the limited sample size and re-identification risk, individual participant data will not be shared. Only de-identified, aggregated results will be reported.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Craving Management and Alternative Behavior Enhancement Program

3
Abonnieren